Table 3.

Subantimicrobial dose doxycycline (SDD) effects on serum inflammatory biomarker levels over the two-year clinical trial

Inflammatory Biomarker		Placebo Group (n =62 subjects)			SDD Group (n =51 subjects)			p-value*
		Median	Mean	SD	Median	Mean	SD
hs-CRP (mg/L)								0.02
Baseline		2.89	3.33	1.82	3.41	4.35	3.92
One Year		2.97	3.45	2.37	2.72	3.54	3.21
Two Year		2.80	3.20	1.99	2.70	3.47	2.79
Myeloperoxidase (ng/ml)								0.2
Baseline		75.63	88.70	63.60	72.61	88.28	52.74
One Year		77.61	96.30	56.81	76.41	90.33	60.42
Two Year		85.39	94.17	44.23	79.04	91.78	51.90
MMP-9 (92 kilodalton)								<0.0001
Baseline		347.84	344.48	42.31	333.13	341.15	45.18
One Year		367.23	355.08	50.64	327.52	325.31	46.64
Two Year		360.80	355.04	56.66	314.80	322.25	49.02
MMP-2 (72 kilodalton)								0.2
Baseline		201.81	203.66	32.12	203.33	204.35	35.81
One Year		199.09	202.99	35.58	199.11	201.13	37.49
Two Year		200.41	204.33	38.19	192.94	194.99	35.90
MMP-8 (ng/ml)								0.2
Baseline		21.48	30.01	24.85	21.78	28.81	26.60
One Year		21.60	25.02	17.37	20.59	25.04	19.47
Two Year		22.29	32.70	31.43	21.16	25.67	17.61
TIMP-1 (scanning units)								0.7
Baseline		3.10	3.59	2.43	2.90	3.38	2.37
One Year		3.02	3.51	2.15	2.58	3.05	2.14
Two Year		3.24	3.45	2.18	3.15	3.37	2.14

^*p-values correspond to the comparison of aggregated 1-year and 2-year mean (MMP-9 and MMP-2) or median (hs-CRP, myeloperoxidase, MMP-8, and TIMP-1) biomarker measures between SDD and placebo subjects.

SD= standard deviation

hs-CRP= high-sensitivity C-reactive protein

MMP= matrix metalloproteinase

TIMP= tissue inhibitor of metalloproteinases